Further, this study characterized a model looking at TNBC, however ER+HER2− patients had a statistically significantly worse OS, therefore there are likely other breast cancer patient populations with EGFR amplification and PI3K alteration who might benefit from this dual therapy (Fig. S1). This evidence concerns the gene EGFR and breast carcinoma.